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G Fornaciari, C Salvarani, M Beltrami, P Macchioni, 
RW Stockbrügger, MG Russel. Musculoskeletal manifestations
in inflammatory bowel disease. Can J Gastroenterol
2001;15(6):399-403. Muscoloskeletal manifestations are the
most common extraintestinal complications of inflammatory
bowel disease. Wide ranges in prevalence have been reported,
depending on the criteria used to define spondylarthropathy. In
1991, the European Spondylarthropathy Study Group developed
classification criteria that included previously neglected cases of
undifferentiated spondylarthropathies, which had been ignored in
most of the oldest epidemiological studies on inflammatory bowel
disease. The spectrum of muscoloskeletal manifestations in
inflammatory bowel disease patients includes all of the clinical
features of spondylarthropathies: peripheral arthritis, inflamma-
tory spinal pain, dactylitis, enthesitis (Achilles tendinitis and
plantar fasciitis), buttock pain and anterior chest wall pain.
Radiological evidence of sacroiliitis is common but not obligatory.
The articular manifestations begin either concomitantly or subse-
quent to the bowel disease; however, the onset of spinal disease
often precedes the diagnosis of inflammatory bowel disease. The
prevalence of the different muscoloskeletal manifestations is simi-
lar in ulcerative colitis and Crohns disease. Symptoms usually dis-
appear after proctocolectomy. The pathogenetic mechanisms that
produce the muscoloskeletal manifestations in inflammatory
bowel disease are unclear. Several arguments favour an important
role of the intestinal mucosa in the development of spondy-
larthropathy. The natural history is characterized by periods of
flares and remission; therefore, the efficacy of treatment is difficult
to establish. Most patients respond to rest, physical therapy and
nonsteroidal anti-inflammatory drugs, but these drugs may acti-
vate bowel disease. Sulphasalazine may be recommended in some
patients. There is no indication for the systemic use of steroids.
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Manifestations musculo-squelettiques et mal-
adies inflammatoires de lintestin
RÉSUMÉ : Les manifestations musculo-squelettiques sont les complica-
tions extra-intestinales les plus fréquentes des maladies inflammatoires
de lintestin. La prévalence de la spondylarthropathie varie beaucoup
selon les critères utilisés. En 1991, le groupe détude européen sur la
spondylarthropathie a élaboré des critères de classification applicables
aux cas autrefois négligés de spondylarthropathie indifférenciée et
écartés de la plupart des premières études épidémiologiques sur les mal-
adies inflammatoires de lintestin. Les manifestations musculo-squelet-
tiques des maladies inflammatoires de lintestin comprennent tous les
signes cliniques de la spondylarthropathie : arthrite périphérique,
douleurs rachidiennes inflammatoires, dactylite, enthésite (tendinite
achilléenne et fasciite plantaire), pygalgie et douleurs thoraciques
antérieures. Les signes radiologiques de sacro-iléite sont fréquents mais
non constants. Les manifestations articulaires apparaissent en même
temps que la maladie de lintestin ou plus tard; toutefois, laffection
médullaire commence souvent avant la pose du diagnostic de maladie
inflammatoire de lintestin. La prévalence des manifestations musculo-
squelettiques est la même pour la rectocolite hémorragique et la maladie
de Crohn. Les symptômes disparaissent généralement après la procto-
colectomie. On ne comprend pas très bien les mécanismes
pathogéniques à lorigine des manifestations musculo-squelettiques des
maladies inflammatoires de lintestin. Plusieurs arguments permettent de
croire que la muqueuse intestinale joue un rôle important dans lappari-
tion de la spondylarthropathie. Lévolution spontanée se caractérise par
des périodes de poussée et de rémission; aussi lefficacité du traitement
est-elle difficile à déterminer. La plupart des patients réagissent bien au
repos, à la physiothérapie et aux anti-inflammatoires non stéroïdiens,
mais ceux-ci peuvent réveiller la maladie de lintestin. La sulfasalazine
peut convenir chez certains patients. Rien ne justifie le recours systéma-
tique aux stéroïdes.
The occurrence of extraintestinal manifestations inpatients with inflammatory bowel disease (IBD) has
been well recognized for many years; these manifestations
are listed in Table 1. Muscoloskeletal disorders are the most
common extraintestinal findings in both ulcerative colitis
(UC) and Crohns disease (CD). In 1930, Bargen (1)
described, for the first time, arthritis complicating UC; in
the following years, it was commonly believed that arthritis
in patients with IBD was rheumatoid arthritis. After the
introduction of the Rose-Waaler agglutination test, which
helped to distinguish coincidental cases of rheumatoid
arthritis, the term colitic arthritis was proposed, and the
first attempt was made to categorize the rheumatic com-
plaints (2). Colitic arthritis was defined as recurrent, brief
attacks of synovitis, usually asymmetrical and associated
with exacerbation of intestinal symptoms, without progres-
sion to deformity. In 1976, Wright and Moll (3) proposed
the inclusion of enteropathic arthropathy among the
seronegative spondylarthropathies. UC and CD are not the
only gastrointestinal disorders associated with rheumatolog-
ical complications. As reported in Table 2, enteropathic
arthropathy is described in several other conditions as well. 
DEFINITIONS
Arthritis associated with IBD belongs to the category of
spondylarthropathies, which consists of several disorders
(reactive arthritis, psoriatic arthritis, and ankylosing
spondylitis in its juvenile and adult form). Two clinical
patterns can occur: peripheral arthritis or axial disease.
However, the clinical spectrum of spondylarthropathies is
wider and includes other manifestations (Table 3). In
1991, the European Spondylarthropathy Study Group
(ESSG) proposed new classification criteria (Table 4) that
were easy to apply in clinical practice, with the aim of
including previously neglected cases of undifferentiated
disease (4). These criteria resulted in a sensitivity of 86% and
a specificity of 87% in the diagnosis of spondylarthopathies
(4). These criteria are superior to the New York modified
criteria (Table 5) (5) for the diagnosis of ankylosing
spondylitis; the New York modified criteria have a low sen-
sitivity and are inadequate in describing the full clinical
spectrum of spondylarthropathies (in particular, the undif-
ferentiated forms). 
In daily practice, a presumptive diagnosis of spondyl-
arthropathies is usually supported by radiological evidence
of sacroiliitis. However, the presence of sacroiliitis is a very
frequent, but not necessarily early and obligate, manifesta-
tion of these conditions. 
Some clinical characteristics are common to all forms of
spondylarthropathies:
 Peripheral arthritis predominantly located in the 
lower limb (asymmetric)
 Tendency to sacroiliitis on x-ray
 Absence of rheumatoid factor
 Absence of subcutaneous nodules and other 
extra-articular features of rheumatoid arthritis
 Association with anterior uveitis
 Familial aggregation
 Association with human leukocyte antigen 
(HLA)-B27
EPIDEMIOLOGY
Differences in patient selection and in the definition of
spondylarthropathy can explain, in part, the wide range in
the prevalence of musculoskeletal disorders reported previ-
ously in IBD. Prevalence of peripheral arthritis has been
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TABLE 1
Extraintestinal manifestations of inflammatory bowel
disease
Area Manifestation
Liver Fatty change, primary sclerosing cholangitis, pericholangitis  
Skin Erythema nodosum, pyoderma gangrenosum, aphthous 
ulceration of the mouth, Sweets syndrome  
Eyes Episcleritis, anterior uveitis  
Joints Peripheral arthritis and sacroiliitis/ankylosing spondylitis
Systemic Amyloidosis  
Other Thrombosis, nephrolithiasis, cholelithiasis, pericarditis, 
lung diseases
TABLE 2
Classification of enteropathic arthritis
Infectious  Reactive arthritis (eg, Shigella, Salmonella, Yersinia, 
Campylobacter, Giardia lamblia)  
Spondylarthropathy in inflammatory bowel disease  
Miscellaneous  Arthritis observed in ileojejunal bypass, celiac disease, 
Whipples disease, collagenous colitis  
TABLE 3
Muscoloskeletal manifestations of spondylarthropathies
Peripheral arthritis  One or more swollen and tender joint(s);
the synovitis is asymmetric and predominantly in lower limbs
Inflammatory spinal pain*  Symptoms of back pain in lumbar, dorsal 
or cervical regions associated with at least four of the following:
 Onset before age 45 years
 Insidious onset
 Improved by exercise
 Associated with morning stiffness
 Duration of at least three months  
Dactylitis  Evidence of sausage digit on examination  
Peripheral enthesitis  Achilles tendinitis and/or plantar fasciitis  
Buttock pain  
Anterior chest wall pain  
*Criteria of Calin et al (reference 43)
reported to be 11% to 20% (6,7). Ankylosing spondylitis
has been diagnosed in 3% to 6% of patients with IBD; how-
ever, radiological evidence of sacroiliitis has been reported
much more frequently (14% to 20%). In UC, a higher fre-
quency of axial involvement (43%) was reported by Scarpa
et al (8). Of the patients studied by these authors, 25% sat-
isfied the modified New York criteria for ankylosing
spondylitis (5). In 14 (18%) additional patients, inflamma-
tory spinal pain was the only rheumatological manifesta-
tion. In an inception cohort of newly diagnosed IBD
patients (9), 30.7% had at least one muscoloskeletal mani-
festation, 18.5% satisfied the ESSG criteria for spondyl-
arthropathy (4), and 2.6% satisfied only the criteria for
ankylosing spondylitis (5; unpublished data). The results of
these two studies show that the clinical spectrum of
rheumatological manifestations is broader than that defined
by spondylarthropathy criteria and that the prevalence of
rheumatological findings in IBD may be higher than
reported in the oldest studies.
There are no major differences between UC and CD in
the occurrence of spondylarthropathy; it seems to be more
prevalent in UC patients with chronic intermittent or con-
tinuous symptoms (10), and in ulcerative pancolitis (7). The
presence of peripheral arthritis is frequently associated with
other extraintestinal manifestations, such as erythema
nodosum and anterior uveitis (11,12). There is a strong asso-
ciation between peripheral arthritis and colonic localization
of CD (12,13). A recent prospective study reported that
peripheral arthritis occurred more frequently in patients
with CD than in patients with UC (20.2% compared with
11.0%, respectively) (12).
CLINICAL COURSE
Although in most cases intestinal symptoms coincide with
or precede the articular manifestations, spinal involvement
can precede the diagnosis of IBD. The onset of peripheral
arthritis is often abrupt, with spontaneous pain, erythema,
hyperemia and effusion. The joints of the lower limb are
most commonly affected, but elbows, metacarpophalangeal
joints and shoulders can be involved as well (14). The
peripheral arthritis is frequently self-limiting and nonde-
forming, but may become erosive and chronic in a limited
number of patients (15). A new classification of peripheral
arthritis has been proposed according to presentation, joint
involvement and course of the disease (Table 6) (16).
Clinically, type 1 arthropathy was similar to reactive (infec-
tious) arthritis, with self-limiting attacks of oligoarthritis,
while type 2 arthropathy was reported to run a more severe
course independent of IBD activity. This classification is
helpful to divide these syndromes into subgroups, but its
usefulness has to be confirmed in clinical practice.
Axial involvement in IBD patients includes radiological
evidence of sacroiliitis, ankylosing spondylitis and undiffer-
entiated spondylarthropathies. Usually, there is no associa-
tion between the severity of bowel disease and the course of
spinal involvement. The association with other extrain-
testinal manifestations is less evident than in peripheral
arthritis. Symptoms at onset are similar to idiopathic anky-
losing spondylitis: the patient complains of low back pain
with morning stiffness, and alternating buttock or chest
pain. The back pain is usually exacerbated by prolonged sit-
ting or standing, or after night rest.
Usually, arthritic symptoms disappear after proctocolec-
tomy (13); however, joint symptoms may reappear after
restorative proctocolectomy (17,18). The relationship
between the inflammation of reconstructed ileal pouch (pou-
chitis) and the occurrence of arthropathy is unclear. A recent
well planned prospective case-control study showed no cor-
relation between occurrence of pouchitis and occurrence of
arthropathy in UC patients (18).
Arthritis and IBD
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TABLE 4
The European Spondylarthropathy Study Group criteria for
spondylarthropathies*
Inflammatory spinal pain or synovitis (asymmetric, predominantly 
in lower limbs) and any one of the following:
 Positive family history
 Psoriasis
 Inflammatory bowel disease
 Alternate buttock pain
 Enthesopathy
These criteria have a sensitivity of 77% and a specificity of 89%
If sacroiliitis (radiological evidence) is added to the criteria, the sensitiv-
ity and specificity are 86% and 87%, respectively. Data from reference 4  
TABLE 5
Modified New York criteria for the diagnosis of ankylosing
spondylitis
Unilateral sacroiliitis grade 3 or 4, or bilateral sacroiliitis grade 2 to 4 
together with at least one of the following:
 Low back pain of at least three months duration improved 
by exercise and not relieved by rest
 Limited motion of lumbar spine in sagittal and 
frontal planes
 Decreased chest expansion relative to normal values for 
age and sex  
Data from reference 5
TABLE 6
Classification of peripheral arthropathy
Type 1 (pauciarticular)
 Less than five joints
 Acute, self-limiting attacks (less than 10 weeks)
 Often coincides with relapses of inflammatory bowel disease
 Strongly associated with other extraintestinal manifestations  
Type 2 (polyarticular)
 Five or more joints
 Symptoms usually persist for months to years
 Course independent of inflammatory bowel disease
 Associated only with uveitis  
Data from reference 16
DIAGNOSIS
The diagnosis of arthropathy in IBD patients is mainly
based on history and clinical evaluation; the importance of
clinical evaluation performed by a rheumatologist has been
stressed previously (8). For the detection of sacroiliitis,
conventional radiography, bone scanning, computed
tomography and magnetic resonance imaging are used
(14,19). In clinical practice, the diagnosis of sacroiliitis is
accurately assessed by a simple pelvic x-ray (20). Sacroiliac
joint involvement is graded according to the New York cri-
teria (21).
The diagnosis of peripheral arthritis is clinical. The evi-
dence of joint swelling or effusion is diagnostic. Radiographs
of the involved joints usually show no abnormalities. Erosive
disease of the hip, as well as metacarpophalangeal and
metatarsophalangeal joints, has been reported (22,23).
Synovial fluid analysis and histology of synovial tissue usu-
ally show a nonspecific inflammation (11). 
No association with HLA-B27 is present in peripheral
arthritis. In ankylosing spondylitis, the association with
HLA-B27 is less strong (50% to 75%) than in the idio-
pathic form (90% to 95%) (8,24,25). 
PATHOGENESIS
The pathogenesis of peripheral arthritis is unclear; the role
of bacterial antigens, such as those in reactive arthritis and
arthritis following intestinal bypass surgery, seems to be
important (26). Several studies have focused on an impor-
tant gut-synovium axis (11,26-28). Furthermore, a cross-
reactivity between gut bacteria and cartilage in patients
with CD has been demonstrated (29).
Genetic predisposition may not be as important in
patients with IBD who have spondylitis as in patients with-
out IBD who have spondylitis, because these latter patients
have much stronger association with HLA-B27 (8,24,25).
The altered gut permeability could be a key factor in the
development of spondylarthropathy.
The relationship between seronegative spondylarthropa-
thy and IBD is very interesting. A non-negligible number of
patients may be affected by rheumatological symptoms
many years before the diagnosis of IBD (16). Recent studies
have suggested that 6% of patients with spondylarthropathy
will develop IBD. However, patients with negative gut his-
tology at the time of arthritis will never develop IBD
(30,31). In one study, colonoscopy was performed in 118
patients with various inflammatory and noninflammatory
joint conditions. Endoscopic lesions were reported in 44%
of patients with spondylarthropathy (32), and 26% of
patients had histology consistent with CD. According to
these data, it can be hypothesized that gut and joint inflam-
mation are coincidental, and that they can be triggered by
the same agent. The sharing of certain peptides by colonic
epithelium, ciliary processes of the eye and chondrocytes of
the joints is a possible pathogenic mechanism (33) that
could also explain the association of arthritis with other
extraintestinal manifestations.
The inflammatory lesions in pouchitis are different from
those present in UC, because pouchitis usually responds to
antibiotic treatment (34). Studies exploring the relation-
ship between arthropathy and pouchitis may be very useful
in clarifying the pathogenic mechanisms of joint involve-
ment in pouchitis. 
TREATMENT
The natural history of muscoloskeletal manifestations in
IBD is characterized by alternating periods of flares and
spontaneous remission; therefore, the usefulness of treat-
ment is difficult to assess. The aims of therapy are to reduce
inflammation, and to prevent disability or deformity.
In general, patients are managed by simple means: rest,
physical therapy and intra-articular steroid injection. In
patients with axial involvement, intensive physiotherapy is
useful to prevent spinal joint fusion and to maintain opti-
mal motility (14,35). Nonsteroidal anti-inflammatory drugs
(NSAIDs) are usually prescribed to control peripheral
arthritis, back pain and stiffness. Caution is necessary
because these drugs may activate quiescent IBD (36,37). In
patients with joint symptoms preceding IBD onset, it has
been claimed that there is a causal relationship of IBD onset
with NSAID therapy (11,38).
In axial involvement, sulphasalazine (SASP) has been
recommended as the drug of choice, and a shift from
mesalazine to SASP has been suggested if the colon is
intact (34). Several placebo controlled trials have reported
a beneficial effect of SASP (39,40). The efficacy of SASP
appears to be related to sulphapyridine, although this ques-
tion has not been completely answered (41). Data about
the long term results of SASP treatment are more scarce;
the drug seems to achieve better results on peripheral
arthritis than on axial involvement (40).
Other slow acting agents, such as azathioprine and 
6-mercaptopurine, have not been studied as closely (42). The
occurrence of arthritis is not an indication for steroid therapy;
however, if the previously reported treatments are scarcely
effective, a short course of steroids is mandatory. The sponta-
neous remission of joint symptoms, particularly in peripheral
arthritis, must always be considered for the management of
patients with rheumatic symptoms secondary to IBD. 
CONCLUSIONS
Inflammatory bowel disease is a heterogeneous disorder in
which patients manifest a spectrum of symptoms related to
intestinal and extraintestinal manifestations. Muscoloskeletal
manifestations are the most common IBD extraintestinal
manifestations and may be present in 30% of patients. Their
spectrum is wider than that defined by the spondylarthropa-
thy criteria. In most cases, intestinal symptoms coincide with
or precede articular manifestations. The gut-joint axis
appears to be an important pathogenic factor. Rest, physical
therapy, intra-articular steroid injection and NSAIDs are
usually prescribed to control peripheral arthritis, back pain
and stiffness. SASP seems to be more effective for peripheral
arthritis than for axial disease.
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